



INDIA GLYCOLS LIMITED



Plot No. 2-B, Sector -126, NOIDA-201304, Distt. Gautam Budh Nagar, Uttar Pradesh, Tel. : +91 120 6860000, 3090100, 3090200
Fax : +91 120 3090111, 3090211 E-mail : iglho@indiaglycols.com, Website : www.indiaglycols.com

26th May, 2023

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street, Mumbai – 400 001

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

Scrip Code: 500201

Symbol: INDIAGLYCO

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation

Further to our letters dated 24th May, 2023 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, an investor presentation is attached for the information of the investors.

The same is also being hosted on the Company's website at www.indiaglycols.com.

This is for your information and records please.

Thanking you,

Yours truly,
For India Glycols Limited

Ankur Jain
Head (Legal) & Company Secretary
Encl: A/a



India Glycols Limited

*Positive Impact
Bio-based Ingredients and
Performance Chemicals*

*Investor Presentation
Q4 & FY23*

This presentation and the following discussion may contain “forward looking statements” by India Glycols Limited (“IGL” or the company) that are not historical in nature. These forward-looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of IGL about the business, industry and markets in which IGL operates.

These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond IGL’s control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of IGL.

In particular, such statements should not be regarded as a projection of future performance of IGL. It should be noted that the actual performance or achievements of IGL may vary significantly from such statements.

Q4 & FY23 Performance



Q4FY23 vs Q4FY22

FY23 vs FY22

Gross Turnover

1,616 Cr
8.1 %

Net Turnover

619 Cr
-3.6%

Gross Turnover

6,642 Cr
+0.6 %

Net Turnover

2,651 Cr
-7.6%

EBITDA

100 Cr
+ 19.0%

EBITDA Margin

16.1%
+ 306 bps

EBITDA

319 Cr
+15.4%

EBITA Margin

11.9 %
+ 237 bps

- Overall, business has shown a good growth momentum during the quarter
- Margin improvement supported by cost actions as well as focus on better margin business

- Gross Turnover saw a modest growth in FY23, despite a challenging environment
- Net Turnover – impact of transfer of EOD business to the JV, some poor margin business discontinued.
- RM and Energy cost pressure on the margins for majority of FY23
- Cost mitigation actions has helped Margin improvement

Other Highlights

- Cost pressures continued with high international ethanol prices. Slight softening energy prices and significant reset on freights. Some signs of softening future ethanol prices.
- Grain Plants commissioned, originally planned capacity achieved– helping mitigate impact of huge feedstock price increases. Working on further debottlenecking and increasing capacity. As a result, imports of ethanol have been completely stopped
- NSU project as per plan – one unit commissioned successfully, Product Development and Business Development work in progress with several customers –domestic as well as International. Initial commercial supplies have started.
- Successfully completed the EU-GMP audit conducted by the EDQM (European Directorate for the Quality of Medicines)at our EB plant to certify that our API's are in line with the required European standards of quality, safety and efficacy
- JV – Weak quarter compared to prior year, strong topline growth for the year but margins have been under pressure due to cost pressures on raw material.
- During the quarter, company sold its entire stake in Shakumbari Sugar and Allied Industries Limited. The sale of the parent Company's entire investment in equity shares and preference shares of the Subsidiary Company is contemplated in one or more tranches to be completed on or prior to 31 May 2023, subject to terms and conditions – *A Non-Core Asset*



Bio-based Specialities and Performance Chemicals (BSPC)

- Q4 Revenue at Rs. 389 Cr., down 9.3%
- FY23 Revenue at 1,705 Cr. Down 15.9%
- EBITDA for Q4 up 12%, for FY23 up 17%
- Q4 EBITDA margin at 15 % up 300 bps
- FY EBITDA margin at 9.7 % up 270 bps
- Business transferred to JV was part of Q1'2021-22 results for BSPC
- Focus on better margin business. Discontinued some poor margin business.
- Operational changes to bring down costs
- Developing new niche customers under Bio-MEG business
- Grain ENA is now available post commissioning of production, helping mitigate RM cost
- NSU progress as per plan –commissioning in progress.

Potable Spirits (PS)

- Q4 Revenue up by 6% on YoY basis,
- FY23 Revenue up by 10% on YoY basis
- EBITDA for Q4 up 32%, for FY23 up 13%
- Q4 EBITDA margin at 16 % up 300 bps
- FY EBITDA margin at 14% up 50 bps
- Branded Country Spirits maintains strong position in UP and Uttarakhand.
- Packaging material costs are stabilizing and giving room for margin improvement
- Policy changes in Delhi reverted to only government-controlled bodies since Sep 22 – better from the perspective of managing outstanding.
- Price rise given by the Govt of UP is expected to have a positive impact in the upcoming Financial Year

Ennature Biopharma (EB)

- Q4 Revenue up by 16.7% on YoY basis,
- FY23 Revenue up by 22.7% on YoY basis
- EBITDA for Q4 up 15%, for FY up 23%
- Q4 EBITDA margin at 30.2% up 30 bps
- FY EBITDA margin at 28.4% up 20 bps
- 4X growth in Nicotine business segment - 4X compared to last year
- Maintained leadership position in Thiocolchicoside in a challenging market
- Dependence on APIs business reduced.
- Focus on building branded Nutraceuticals range by launching Xanthogreen™, Gingeren™ and Turminova™ in various markets
- Launch of Xanthogreen as the key ingredient in a multi-vitamin finished formulation in US

Financial Summary - Consolidated



INDIA GLYCOLS LIMITED

Particulars (In INR Cr)	Q4FY23	Q4FY22	Y-o-Y (%)	Q3FY23	Q-o-Q (%)	FY23	FY22	Y-o-Y (%)
Revenue from operations (net of excise)	619	642	(3.6%)	554	11.9%	2,651	2,868	(7.6%)
Other Income	4	5	(6.9%)	7	(36.1%)	24	22	10.9%
Total Income	624	647	(3.6%)	561	11.3%	2,675	2,890	(7.4%)
Cost of Material Consumed	324	362	(10.6%)	303	7.0%	1,582	1,921	(17.6%)
% of Sales	51.9%	56.0%	(408 bps)	54.0%	(206 bps)	59.2%	66.5%	(733 bps)
Employee Benefit Expenses	26	15	74.3%	23	14.1%	89	89	(0.4%)
% of Sales	4.2%	2.3%	188 bps	4.1%	10 bps	3.3%	3.1%	23 bps
Other Expenses	173	185	(6.5%)	159	9.0%	684	603	13.6%
% of Sales	27.8%	28.6%	(86 bps)	28.3%	(58 bps)	25.6%	20.8%	473 bps
EBITDA	100	84	19.0%	76	32.0%	319	277	15.4%
EBITDA Margin	16.1%	13.0%	306 bps	13.6%	253 bps	11.9%	9.6%	237 bps
Depreciation	30	21	44.1%	21	38.6%	94	80	17.0%
EBIT	71	64	10.9%	55	29.4%	225	196	14.8%
Finance Cost	26	18	43.6%	27	(2.9%)	100	70	43.5%
Exceptional Items	-	(19)	-	28	-	28	221	(87.3%)
Share of net profit / (loss) of joint venture	1	5	(73.7%)	(2)	-	11	21	(45.5%)
PBT	46	32	43.4%	53	(14.3%)	165	369	(55.3%)
Tax Expenses	6	(35)	-	3	79.6%	24	39	(39.2%)
Profit / (Loss) after tax from continuing operations	40	67	(40.6%)	50	(20.4%)	141	330	(57.2%)
Profit / (Loss) after tax from discontinued operations	-	-	-	-	-	-	10	-
Profit / (Loss) for the period	40	67	(40.6%)	50	(20.4%)	141	340	(58.5%)
PAT Margin for continued operations	6.4%	10.4%	(398 bps)	8.9%	(254 bps)	5.3%	11.4%	(613 bps)
EPS for continued operations	12.9	21.7	(40.6%)	16.2	(20.4%)	45.6	106.5	(57.2%)

Financial Summary - Standalone



INDIA GLYCOLS LIMITED

Particulars (In INR Cr)	Q4FY23	Q4FY22	Y-o-Y (%)	Q3FY23	Q-o-Q (%)	FY23	FY22	Y-o-Y (%)
Revenue from operations (net of excise)	619	638	(3.0%)	553	11.9%	2,650	2,863	(7.4%)
Other Income	4	9	(50.4%)	8	(49.0%)	28	27	4.0%
Total Income	623	647	(3.6%)	562	11.0%	2,678	2,890	(7.3%)
Cost of Material Consumed	324	361	(10.4%)	303	7.0%	1,582	1,920	(17.6%)
% of Sales	51.9%	55.9%	(397 bps)	53.9%	(193 bps)	59.1%	66.5%	(737 bps)
Employee Benefit Expenses	26	15	76.4%	23	14.3%	87	88	(0.5%)
% of Sales	4.1%	2.3%	188 bps	4.0%	12	3.3%	3.0%	22
Other Expenses	173	185	(6.4%)	156	10.8%	683	603	13.3%
% of Sales	27.7%	28.6%	(84 bps)	27.8%	(4 bps)	25.5%	20.9%	466 bps
EBITDA	101	86	17.7%	81	25.3%	325	279	16.6%
EBITDA Margin	16.2%	13.3%	293 bps	14.3%	185 bps	12.1%	9.7%	249
Depreciation	29	19	47.6%	20	40.6%	90	76	18.0%
EBIT	72	66	8.9%	60	20.1%	235	203	16.0%
Finance Cost	26	17	59.8%	26	1.4%	95	62	53.1%
Exceptional Items	-	(39)	-	(18)	-	(18)	201	(108.8%)
Share of net profit / (loss) of joint venture	-	-	-	-	-	-	-	-
PBT	46	11	333.0%	17	176.8%	123	341	(64.1%)
Tax Expenses	6	(8)	-	3	79.6%	24	66	(63.8%)
Profit / (Loss) after tax from continuing operations	40	19	110.8%	13	200.4%	99	275	(64.1%)
Profit / (Loss) after tax from discontinued operations	-	-	-	-	-	-	10	-
Profit / (Loss) for the period	40	19	110.8%	13	200.4%	99	285	(65.4%)
PAT Margin for continued operations	6.4%	2.9%	349 bps	2.4%	406 bps	3.7%	9.5%	(583 bps)
EPS for continued operations	13.0	6.1	110.9%	4.3	200.4%	31.9	88.9	(64.1%)

Segment Performance - Consolidated





INDIA GLYCOLS LIMITED

(In INR Cr)	Q4FY23	Q4FY22	% YoY	Q3FY22	% QoQ	FY23	FY22	% YoY
Bio-based Specialities and Performance Chemicals (BSPC)								
Net Revenue	389	429	(9.3%)	324	20.0%	1,705	2,026	(15.9%)
EBIT	42	43	(2.3%)	30	42.0%	125	121	3.3%
<i>% margin</i>	10.9%	10.1%	79 bps	9.2%	169 bps	7.3%	6.0%	136 bps
Potable Spirits (PS)								
Net Revenue	187	176	6.1%	188	(0.6%)	754	686	10.0%
EBIT	29	23	28.5%	28	5.6%	102	90	13.4%
<i>% margin</i>	15.6%	12.9%	272 bps	14.7%	91 bps	13.5%	13.1%	41 bps
Ennature Biopharma								
Net Revenue	43	37	16.7%	42	4.4%	192	156	22.7%
EBIT	11	10	12.6%	10	10.8%	49	39	23.4%
<i>% margin</i>	26.3%	27.3%	(96 bps)	24.8%	151 bps	25.4%	25.3%	13 bps



Segmental Revenue and EBIT Mix - Consolidated

Revenue Mix



● BSPC
 ● PS
 ● Ennature Biopharma

EBIT Mix



● BSPC
 ● PS
 ● Ennature Biopharma

Commodity Prices are stabilizing




INDIA GLYCOLS LIMITED

Indexed as per the prices in April 2021


↑ 47%

Coal




↑ 45%

Ethanol




↑ 12%

Mild Steel



↓ 66%

Acetic Acid




₹/Kg	
5.2	7.7

₹/BL	
39.4	57.0


₹/Kg	
53.6	60.2

₹/Kg	
122.4	41.5

- Global Ethanol prices that went up during Covid have continued to remained at historic highs
 - Ethanol Blending
 - War - Grain and Energy
 - Energy Prices
 - Climate and Commodity prices
- Extension of Grain deal with Russia to allow export of grain navigating through safe corridor in Black Sea – Bosphorous Strait
- Ukraine (Wheat 10%, Corn 15%, Barley 13%)
- Gas prices in Europe have seen sharp decline
 - € 30 per MW (11 X lower than peak last year)
 - Ample storage and supply from US
 - Russian gas 90% lower than before
- Ethanol plants coming up in Ukraine
- Rising interest rates and weaker prices for Agri commodities e.g wheat, corn, soybean
- Longer term Gasoline usage expected to decline with EV increase
- India worlds largest producer and consumer of sugar now
- To early to predict trend –uncertainty continues



Natural-gas futures prices in northwest Europe



Company Overview



INDIA GLYCOLS LIMITED





Go Green

1st in the world to use Innovative Green Technologies to manufacture bio-based ethylene oxide & derivatives, glycols, glycol ethers and specialties.



Diversified product portfolio with inherent synergies

Bio-based Specialties, Bio-Polymers, Potable Spirits, Gases, Biofuels, Plant based APIs & Nutraceuticals, CarbonSmart range etc.



Global Standards

Compliance with stringent global standards of plant operations, quality and safety.



State-of-the-art manufacturing facilities

Integrated manufacturing facilities located at Kashipur, Gorakhpur and Dehradun, have been approved and certified by international agencies



Global customer & partnerships with reputed global companies

Work closely with global customers in the various industries; catering to high value-added green market constituting multinationals & large corporates



Strengthening Balance sheet


Gearing declined to 0.6x in FY23 from 0.8x in FY20

Amongst world's leading companies manufacturing green technology-based bulk, specialty and performance chemicals, potable spirits, industrial and nutraceuticals

Key Milestones



INDIA GLYCOLS LIMITED



Portfolio

Leading in Bio-based Ingredients and Performance Chemicals




INDIA GLYCOLS LIMITED

Segments	Bio-based Specialities And Performance Chemicals (BSPC) 	Potable Spirits (PS) 	Ennature Biopharma 
Revenue Mix (Consol. FY23)	Net revenue share 64%	Net revenue share 28%	Net revenue share 7%
Products	<ul style="list-style-type: none"> □ Bio-based Glycols (MEG, DEG, TEG and Heavy Glycols), Glycol Ethers & Acetates □ Ethylene Oxide Derivatives (EODs) (transferred to a JV company) □ Bio Fuel, Bio Polymers, Industrial Gases, Bio-Polymers □ Amines & Plasticizers □ New Areas – Bio-fuels, Bio-FMCG, CarbonSmart and Bio-Fertilizers 	<ul style="list-style-type: none"> □ Indian-manufactured foreign liquor (IMFL) across Whiskey, Vodka and Rum segments □ Branded Country Liquor □ Extra Neutral Alcohol (ENA) 	<ul style="list-style-type: none"> □ Plant based natural APIs □ Thiocolchicoside □ Lutin □ Curcuin □ Astaxanthin □ Nutraceuticals □ Liquid Nicotine & various salts □ Carotenoids
Applications	<ul style="list-style-type: none"> □ Food and Beverage, FMCG □ Health Care & Personal Care □ Paint, Coatings, Home Care □ Automotive sector □ Oil & gas, Metal and mining □ Textiles 	<ul style="list-style-type: none"> □ Beverages, Perfumery, Pharma, Personal Hygiene □ Lifestyle Retail 	<ul style="list-style-type: none"> □ Pharmaceutical □ Personal Care □ Food colours, herbal and spice extracts □ Beverage, dietary supplement, functional food

JV with Clariant: Leaders in in bio-based ethoxylates and derivatives



INDIA GLYCOLS LIMITED



Combining production and distribution capacity, the joint venture is establishing to become a leading supplier of renewable materials to the rapidly growing consumer care market in India and neighbouring countries



Production facilities in India **are supplying to local and global markets**, thus one of the largest Green focused speciality chemicals (EO Derivative) company




Promote new age value added products such as EO-PO co-polymers and other speciality alkoxyates through sustainable green chemistry in the domestic market while expanding footprint in global markets



Exclusive rights to distribute Clariant's entire range of industrial and consumer Specialities business in India, Sri Lanka, Bangladesh and Nepal

¹ Subject to adjustment in accordance with the Business Transfer Agreement

Leveraging synergies to create value-integrated manufacturing for bio-based products





Kashipur

300-acre state of art integrated manufacturing complex

Fermentation – Molasses and Grain Based
Ethanol Distillation, Extra Purification
Biofuels
Grain based Ethanol
Ethylene Oxide, High purity EO
Glycols (MEG, DEG, TEG and derivatives)
Green solvents based on Glycol Ethers and Glycol Ether Acetates
Specialities and Performance Chemicals
Branded CL Bottling
IMFL
Industrial Gases – Oxygen, Nitrogen, Argon, CO2



Gorakhpur

56-acre state of art distillation & bottling complex


Grain based Ethanol
Fermentation
Ethanol Distillation
Ethanol Extra Purification
Ethanol Bio Fuel Grade
Branded CL Bottling
IMFL bottling Tetra
IMFL Glass bottling



Dehradun

160,000 sqft state of art facility

High Purity Extraction
SCFE (Super Critical CO2)
Solvent Extraction
Aqueous Extraction
Bio Fermentation



- ❑ Green Solvents for Industrial and household applications; replacing chlorinated Hydrocarbons
- ❑ Smart Specialty Chemicals including from smart alcohol; alternatives of ingredients from petrochemicals
- ❑ Bio-based Specialties for Health & Personal Care Products; Environment-friendly and consumer friendly
- ❑ Bio-Polymers and Hydrocolloids for high-end applications; for example, Guar
- ❑ Basic building blocks from renewable resources; low carbon footprint, saving GHG emissions
- ❑ Green Brake-fluids, Antifreeze agents and Lubricants; replacing Petroleum derived products
- ❑ Green FMCG products; completely bio-degradable and environment-friendly
- ❑ Ennature R&D focussed of diverse requirements for plant based APIs and Nutraceuticals – patents for Lutein ester extraction

Business Segments



INDIA GLYCOLS LIMITED

- ❑ First in the world to manufacture ethylene oxide and glycols from bio-based feedstocks e.g. Molasses, Grain
- ❑ Largest manufacturer of Bio-based glycols and Bio-based Ethylene Oxide made from renewable feedstock i.e. Molasses
- ❑ Products for a number of end market areas – Automotive, Paints & Coatings, Oil & Gas, Personal Care, Home Care, Textiles, Food etc.
- ❑ Bio Fuels – Special Grade of Ethanol for petrol blending
- ❑ Glycol ethers and acetates: Only manufacturer in India to use a continuous process with world-renowned ‘Sulzer Chemtech’ technology. Reliable supply; integration of its captive feedstock of ethylene oxide and ethyl alcohol
- ❑ Industrial Gases: Cryogenic gases using pioneering air separation technology - Liquid Oxygen and Liquid Nitrogen for captive and external requirements. In addition, Argon, Beverage and Industrial Grade Liquid Carbon Di-oxide (LCO₂), ETO (Ethylene Oxide & Carbon Dioxide Gas Mixtures) are produced
- ❑ Manufacturing of Biopolymers other hydrocolloids products with specialty PO derivatized guar

Figures mentioned in FY20 and FY21 are after taking into consideration the effect of transfer of Ethylene Oxide Derivatives (EOD/Speciality Chemicals & Ethoxylate) division to JV

- ❑ License for operations and sale of Country Liquor in the States of Uttar Pradesh and Uttarakhand. Also operates and sells Indian Made Foreign Liquor (“IMFL”) from its own unit and few tie-up units
- ❑ Company brands are available in the states of Uttarakhand, Uttar Pradesh, Delhi and Himachal Pradesh
- ❑ Several IMLF brands launched in FY 2021-22 – Amazing™ Vodka, Single™ Reserva Whiskey
- ❑ Registered supplier to Indian Defense forces through CSD, continuing brand premiumisation plan, will endeavor to introduce premium brands
- ❑ Extra Neutral Alcohol (ENA), confirming to international standards; exported to Middle East, Africa and Sri Lanka, apart from being supplied to many of India's premium liquor brands.
- ❑ ENA is also used as a reaction aid in the pharmaceutical industry and as a volatile carrier of flavours and fragrances
- ❑ Tie-up with Bacardi for bottling of their products at the Kashipur bottling unit
- ❑ Continuing brand premiumisation plan to introduce premium brands in **Whisky and Vodka** categories will further strengthening the Company’s brand portfolio
- ❑ Grain based ethanol will help push up PS segment margins and also help drive sales through improved competitiveness; commercial production has started at both Kashipur and Gorakhpur locations

Figures mentioned in FY20 and FY21 are after taking into consideration the effect of transfer of Ethylene Oxide Derivatives (EOD/Speciality Chemicals & Ethoxylate) division to JV

- ❑ Operates in the space of Nutraceuticals, Phytochemicals & health supplement ingredients. One of the leaders in Complex phytochemicals chemistry in India
- ❑ Global leader in Thiocolchicoside, a highly potent muscle relaxant API
- ❑ Advanced production capabilities, including organic certified Fluid extraction & ethanol (solvent) extraction, for production of Standardized Botanical Extract, Phytochemicals, Food Supplements, Spice Extracts and Active Pharmaceutical Ingredients (API) of natural plant origin
- ❑ Ennature maintains germ plasm for herbs like artemisia, stevia, rosemary, marigold and sage among others, in ~100 acres; maintained under experienced agronomists. These are transferred to farmers who have contract cultivation agreements with IGL for buy-back
- ❑ Successful products in the recent past include Liquid Nicotine & various salts, for cigarette replacement therapy. Additionally, the Company has developed molecule Asiaticoside/ Madecassosides apart from existing Centella Asiatica for skin repair
- ❑ Also launched Maxicura (a curcumin formulation) in nanotized form which is more bioavailable than curcumin itself
- ❑ New APIs to be launched – Ex: Hyoscine butyl bromide processed from dubosia leaves, used to treat crampy abdominal pain, esophageal spasms, renal colic, and bladder spasms

XANTHOGREEN™




Marigold
SPECIALITY INGREDIENTS

GINGEREN™




Taste Masked Granules
WITH HIGH TOLERABILITY

TURMINOVA™ B



BDMC
THE MOST POTENT
ANTIOXIDANT CURCUMINOID

Maxicura®



172 Folds More FREE Curcumin
Clinically Validated

40% Microencapsulated Curcuminoid	3 Prolonged Stability	Instant Cold Water Soluble	NO After Taste
---	-----------------------------	-------------------------------	----------------------

Branded
Range



- **Glycols** are used for the manufacture of polyester yarn, fibre, film and resin and as an automobile coolant
- **Bio-glycols** cater to the beverage and food industry's packaging requirement of PET bottles and polyester film
- **Ethyl / Butyl glycol ethers and its acetates**, find application in the Textile, Oil & Gas, Paint and Coating, Automotive brake fluid, Pharma and Electronic Chemical industries
- **Performance chemicals** in automotive sector include brake fluid and anti-freeze coolant. Other areas are Textile, Agrochemicals, Paint, Oil & Gas, Personal Care, Detergents, Paper, Mining etc.
- **Power Alcohol** is used by Oil Manufacturing Companies ('OMC's) for blending in Petrol as per Govt. Policy
- **ENA – Extra Neutral Alcohol** is high purity ethanol which is used in Beverages, Perfumery, Pharma, Personal Hygiene
- **Industrial Gases** have a wide range of use across chemical processing, Glass manufacturing, Healthcare, Metal fabrication/ production, Steel, Petroleum recovery and refining, Pulp & paper, Wastewater treatment, Electronics, Lighting, Construction, Food industry
- **Liquid CO2** is used in Food Industry (Carbonation of beer and soft drinks, Food Preservation & Transportation, Dry Ice), Manufacturing industry (CO2 welding, Foundries, Fire Extinguishers), Agriculture (Green houses, Grain silos)
- **ETO** is used in Sterilization of disposable medical devices, and other sterilization uses
- **Food Quality Natural Gum** has application in Frozen Foods, Ice-Cream, Bakeries, Beverages & Sauces
- **Industrial Quality Natural Gum** is used in Personal Care, Mining, Paper, Construction, Paint, Textile industries and Oil & Gas applications

Figures mentioned in FY20 and FY21 are after taking into consideration the effect of transfer of Ethylene Oxide Derivatives (EOD/Speciality Chemicals & Ethoxylate) division to JV

Growth Drivers



INDIA GLYCOLS LIMITED

- ❑ High prospects of growth of industry sectors being serviced by IGL – Personal Care, Automotive, Packaging, Beverages, Oil & Gas, Home Care, Pharma, Nutraceuticals etc, Textiles – most expected to grow at near double digit or more
- ❑ Increasing consumer awareness and demand for sustainable products
- ❑ Companies taking steps to significantly decrease carbon footprint in line with USDG targets
- ❑ Growing demand for natural and safer products in pharma, nutraceuticals, cosmeceuticals, food ingredients
- ❑ IGL is ideally placed to seize the opportunity arising out the increasing demand for ingredients derived from renewable resources and CarbonSmart feed stocks; alternatives to ingredients derived from fossil fuels
- ❑ State-of-the-art of technology adopted to produce specialty chemicals of global quality standards
- ❑ Regular R&D and innovation support for products as well as their applications
- ❑ IGL has established itself as a reliable partner for its customers, with high degree of sustainability
- ❑ Collaborative R&D tie-ups with leading global players for forward and backward integration of products
- ❑ Success stories of IGL from the experiences so far will serve as the key driver of growth

Growth of Bio-EOD from JV

Opportunities in Novel Specialities based on green technology

Focusing on a New Range of Value-Added Products

- ❑ New NSU plant is expected to be commissioned in two phases, with the first phase in Q1FY24. For this, IGL has already identified a number of product lines and has already started sampling and taking orders for these product lines, which include carbon smart ethoxylates, oilfield products, bio-EO based Amines, plasticizers, cosmetic products, among others
- ❑ Under the EB segment also, the company is focusing on some higher-value and pharma-based nicotine derivatives businesses
- ❑ IGL continues to maintain a leadership position in Uttar Pradesh and Uttarakhand in the PS segment, the business is posting consistent development primarily backed by an increase in the sales of branded country liquor category

Lowering Energy and Coal Prices

Focus on actions to lower energy and coal prices are also expected to help IGL achieve higher operating margins in the coming quarters

Agreement with ReNew Green

The company has executed an agreement with Renew Green to procure captive wind and solar hybrid power which is expected to begin next year and will result in further cost savings as well as strengthen the sustainability profile.

Becoming Self- Sufficient and Import Independent

Evaluating a further Capex for grain-based plants in the Kashipur unit from 180 KLPD to 360 KLPD and becoming completely “Atmanirbhar” (self-sufficient) and import independent

Looking to Invest Cash in Core Business

Recognized a gain of Rs. 28 Crores from the sale of its non-core asset - Kashipur Infrastructure and Freight Terminal Pvt. Ltd. and is also expected to receive Rs. 135 Crores over three years, which is pending from JV agreement. This can be invested in the core businesses.

Yearly financial Performance









INDIA GLYCOLS LIMITED

4-year Financial Trajectory - Consolidated



INDIA GLYCOLS LIMITED

In INR
Cr









The difference between excluding and including discontinued business is Ethylene Oxide Derivatives business (EOD/Speciality Chemicals & Ethoxylate) transferred to JV

4-year Financial Trajectory - Consolidated



INDIA GLYCOLS LIMITED



RoE showing is inclusive and excluding discontinued business i.e. Ethylene Oxide Derivatives business (EOD/Speciality Chemicals & Ethoxylate) transferred to JV

Sustainability, ECG and Certifications



INDIA GLYCOLS LIMITED

Environment Stewardship

- World’s first and largest producer of Bio-Based EO and its derivatives
- Next Generation CarbonSmart products from emissions (fossil carbon) - collaboration with LanzaTech & consumer majors like Unilever and Lululemon
- Environment conservation by adopting best practices & Zero Liquid Discharge plants
- Ennature Bio-Pharma – High purity plant-based APIs and Nutraceuticals and Cosmeceuticals
- GHG emissions monitoring as per GHG Protocol along with Life Cycle Impact Assessment of products in respect to various environment aspects

Social Accountability

- Social criteria in consideration of company’s relation with stakeholders and their issues
- Commitment towards Diversity, Human Rights & Grievances
- Zero tolerance towards Child Labour, Bonded Labour and Discrimination in any form
- High Standards and occupational health and safety and maintaining conducive environment
- Commitment to community and employee welfare



Management & Ethical System Certifications – sustaining for over a decade





Thank you

India Glycols Limited

CIN: L24111UR1983PLC009097

Ankur Jain

Company Secretary & Compliance Officer

Head office

2B, Sector-126, Noida

Gautam Budh Nagar

Uttar Pradesh 201304

Tel: +91-120-6860000, 3090100, 3090200

Fax: +91-120-3090111

Email: investor.relations@indiaglycols.com

Ernst & Young LLP

Runjhun Jain

runjhun.jain1@in.ey.com

Rohit Anand

rohit.anand4@in.ey.com

Riddhant Kapur

Riddhant.kapur@in.ey.com



INDIA GLYCOLS LIMITED